216 Users Online
Metabolomics Biomarker Market Segmented By application such as drug designing, personalized medicine and other with indication such as cardiovascular, metabolic diseases, cancer, mental health and infectious diseases
Metabolomics Biomarkers are used for discovery of new insights, assessment method and treatment options for pathological diseases other than the traditional ideas. Metabolites are small molecules which are responsible for cellular processes and metabolism in an organism.
Metabolites are used for biomarker discovery by metabolite profiling in cells, tissues or biofluids. Biomarkers acts as indicators for response in the form of a biological process of a drug, toxin or therapy. Metabolomics biomarkers are also used to evaluate the progress of the disease and provide insights into the underlying pathophysiology.
They are exponentially increasing its applicability for constructing personalized medicine and is considered an essential prerequisite. A disease can induce a change in the normal metabolites concentration and may also propel production of other metabolites which are detected by the researcher and the pathogenesis of the disease is studied.
These changed metabolites are labelled and classified into the groups of responses to different diseases. These are called as metabolomics biomarkers are later used to identify a disease at an early stage, studying the prognosis of disease and predicting the response to a particular treatment. Metabolomics biomarkers enable diseases to be traced with accuracy and sensitivity.
The increasing awareness and applicability of metabolomics biomarkers is predicted to largely influence the expansion of the metabolomics biomarkers market. Metabolomics biomarkers find their application in disease diagnosis since decades and with the current advances in medical science and biotechnology, they are expected to spread their implementation in a vast variety of diseases, including cancer, obesity and unknown diseases.
The increasing expenditure and funds for research and development programs and increased investment in healthcare and life science sector further propels the growth of metabolomics biomarkers in market. Metabolomics biomarkers are also driven by the increasing demand for personalized medicine.
The application of metabolomics biomarkers in early disease diagnosis as well as in understanding the pathogenesis of the disease is luring the manufacturers in metabolomics biomarker market.
On the contrary, the costly nature of the metabolomics biomarkers research creates a barrier for adoption of the product in undeveloped countries. Moreover, these products require expert scientists and usually takes a lot of time which hampers the growth of metabolomics biomarker in the market.
Tentatively, Metabolomics Biomarker Market has been segmented on the basis of application, indication, and end user.
|basis of application||
|basis of indication||
|basis of end users||
Global Metabolomics Biomarker market has witnessed growth due to expanding demand for diagnostics and early detection of diseases. The global market is predicted to boost its expansion owing to the demand for understanding the pathogenesis of diseases. Government initiatives as well as leading player’s investments in the terms of forming research groups and providing funding for cancer research is expected to propel the metabolomics biomarker market over the forecast period. On the basis of application, the market is segment into drug designing, personalized medicine and other.
The personalized medicine segment is expected to majorly contribute to the metabolomics biomarker market over the forecast period. On the basis of indication, Metabolomics Biomarker Market is segmented as cardiovascular, metabolic diseases, cancer, mental health and infectious diseases. As per end users, research laboratories and cancer research centers are expected to be leading in the metabolomics biomarker market during the forecast period.
In the terms of regional and geographical perspective, the global metabolomics biomarker market is categorized into five key regions: North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. In terms of revenue, North America is expected to account for the largest share in the forecast period in the market owing to higher expenditure on research and development as well as presence of higher demand from the end users.
Europe is expected to be the second leading regions in terms of revenue in metabolomics biomarker market over the forecast period due to increasing number of manufacturers and advance research in metabolomics and molecular biology. Middle East & Africa metabolomics biomarker market is expected to register slow growth because of lack of awareness and less expenditure spent on healthcare and research.
Some of the market participants in the global metabolomics biomarker market identified across the value chain include: Agilent Technologies, Inc., Chenomx Inc., Creative Proteomics, Thermo Fisher Scientific, Inc., Biocrates Life Sciences Ag, Metabolon, Inc., Bruker Corporation, Metabolomic Diagnostics Ltd., Biomark Diagnostics Inc., Human Metabolome Technologies America, Inc., and Merck KGaA among others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.